account_balance
Investment manager · 13F filer · SEC CIK 1595725
Rock Springs Capital Management LP
Reported value$2.05Bas of Jun 30, 2026
Positions104 17 new, 13 sold out
Top 10 weight44.0%RVMD alone is 10%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
RVMDRevolution Medicines Inc
10.1%Trimmed −9%
TVTXTravere Therapeutics Inc
6.0%Added +47%
LLYEli Lilly & Co
5.8%
MDGLMadrigal Pharmaceuticals Inc
4.6%Added +2%
MIRMMirum Pharmaceuticals Inc
4.6%
RYTMRhythm Pharmaceuticals Inc
3.8%
KYMRKymera Therapeutics Inc
2.5%Trimmed −9%
ARGXArgenx Se
2.4%Trimmed −46%
ASNDAscendis Pharma A/s
2.2%New
XENEXenon Pharmaceuticals Inc
2.0%Trimmed −10%
SRRKScholar Rock HLDG Corp
1.9%Trimmed −3%
INSMInsmed Inc
1.9%Added +15%
RVMDRevolution Medicines Inc
10.1%Trimmed −9%
TVTXTravere Therapeutics Inc
6.0%Added +47%
LLY5.8%MDGL4.6%MIRM4.6%RYTM3.8%KYMR2.5%ARGX2.4%ASND2.2%XENE2.0%SRRK1.9%INSM1.9%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
RVMD Revolution Medicines Inc 10.1% Trimmed −9%TVTX Travere Therapeutics Inc 6.0% Added +47%LLY Eli Lilly & Co 5.8% HeldMDGL Madrigal Pharmaceuticals Inc 4.6% Added +2%MIRM Mirum Pharmaceuticals Inc 4.6% HeldRYTM Rhythm Pharmaceuticals Inc 3.8% HeldKYMR Kymera Therapeutics Inc 2.5% Trimmed −9%ARGX Argenx Se 2.4% Trimmed −46%ASND Ascendis Pharma A/s 2.2% NewXENE Xenon Pharmaceuticals Inc 2.0% Trimmed −10%SRRK Scholar Rock HLDG Corp 1.9% Trimmed −3%INSM Insmed Inc 1.9% Added +15%
What changed